Does nanodispersion-based paclitaxel injection have better antitumor effects than paclitaxel?

Yes. Currently, researchers have developed a nanoparticle-based concentrate for injection (Nab-paclitaxel), which is a water-soluble formulation of paclitaxel. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby inhibiting cell division. Compared with paclitaxel alone, the nanodispersion-based formulation uses less toxic solvents and a larger dose, resulting in higher paclitaxel concentrations at the tumor site and better safety.

In addition, they compared the antitumor efficacy and toxicity of Nab-paclitaxel with paclitaxel in vitro and in a mouse endometrial cancer model. Nab-paclitaxel is more effective than paclitaxel in inhibiting cancer cell growth. Nab-paclitaxel also causes apoptosis and cell cycle G1 arrest more effectively than paclitaxel. Similar effects were observed in a mouse model of endometrial cancer. However, it remains to be verified in clinical applications.